BRIEF-AtriCure Q3 Adjusted EPS USD 0.18 Vs. IBES Estimate USD -0.05

What happened

AtriCure reported third-quarter adjusted earnings per share of USD 0.18, compared with the IBES estimate of USD -0.05. Revenue was USD 154.5 million versus an estimate of USD 151.2 million, and adjusted EBITDA was USD 26.8 million. The company forecast full-year revenue of USD 606–610 million and adjusted EBITDA of USD 91–94 million.

Confirmed

Global impact / market context

Revenue and adjusted EBITDA both exceeded estimates, while the full-year adjusted EBITDA outlook is above the estimate cited. If that outlook is achieved, stronger operating results could increase cash available for company spending; however, the article gives no explanation of what drove the results or forecast.

Analyst inference

The reported figures are above the cited estimates for third-quarter revenue and adjusted EBITDA, and the forecast range for full-year adjusted EBITDA is above its estimate. Full-year revenue guidance is close to the cited estimate, so the outlook signals a more pronounced improvement in expected earnings than sales.

Analyst inference

What to watch

1. Check subsequent results against the full-year revenue forecast of USD 606–610 million and adjusted EBITDA forecast of USD 91–94 million to see whether the company delivers its outlook. Analyst inference
2. Look for management explanations of revenue and adjusted EBITDA performance; the article reports the figures but does not identify the products, costs, or other factors behind them. Analyst inference
3. Compare later adjusted EBITDA results with the cited IBES estimate of USD 87.5 million to assess whether expectations catch up with the company’s higher forecast. Analyst inference

Evidence

• Original source link unavailable